The α7β0 Isoform of the Complement Regulator C4b-Binding Protein Induces a Semimature, Anti-Inflammatory State in Dendritic Cells
- 15 March 2013
- journal article
- research article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 190 (6), 2857-2872
- https://doi.org/10.4049/jimmunol.1200503
Abstract
The classical pathway complement regulator C4b-binding protein (C4BP) is composed of two polypeptides (alpha- and beta-chains), which form three plasma oligomers with different subunit compositions (alpha(7)beta(1), alpha(7)beta(0), and alpha(6)beta(1)). We show in this article that the C4BP alpha(7)beta(0) isoform (hereafter called C4BP[beta(-)] [C4BP lacking the beta-chain]), overexpressed under acute-phase conditions, induces a semimature, tolerogenic state on human monocyte-derived dendritic cells (DCs) activated by a proinflammatory stimulus. C4BP isoforms containing beta-chain (alpha(7)beta(1) and alpha(6)beta(1); C4BP[beta(+)]) neither interfered with the normal maturation of DCs nor competed with C4BP(beta(-)) activity on these cells. Immature DCs (iDCs) treated with C4BP(beta(-)) retained high endocytic activity, but, upon LPS treatment, they did not upregulate surface expression of CD83, CD80, and CD86. Transcriptional profiling of these semimature DCs revealed that treatment with C4BP(beta(-)) prevented the induction of IDO and BIC-1, whereas TGF-beta 1 expression was maintained to the level of iDCs. C4BP(beta(-))-treated DCs were also unable to release proinflammatory Th1 cytokines (IL-12, TNF-alpha, IFN-gamma, IL-6, IL-8) and, conversely, increased IL-10 secretion. They prevented surface CCR7 overexpression and, accordingly, displayed reduced chemotaxis, being morphologically indistinguishable from iDCs. Moreover, C4BP(beta(-))-treated DCs failed to enhance allogeneic T cell proliferation, impairing IFN-gamma production in these cells and, conversely, promoting CD4(+)CD127(low/neg) CD25(high)Foxp3(+) T cells. Deletion mutant analysis revealed that the complement control protein-6 domain of the alpha-chain is necessary for the tolerogenic activity of C4BP(beta(-)). Our data demonstrate a novel anti-inflammatory and immunomodulatory function of the complement regulator C4BP, suggesting a relevant role of the acute-phase C4BP(beta(-)) isoform in a number of pathophysiological conditions and potential applications in autoimmunity and transplantation. The Journal of Immunology, 2013, 190: 2857-2872.This publication has 58 references indexed in Scilit:
- C1q regulation of dendritic cell development from monocytes with distinct cytokine production and T cell stimulationMolecular Immunology, 2011
- Dendritic cell control of tolerogenic responsesImmunological Reviews, 2011
- Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapiesJournal of Translational Medicine, 2010
- Complement evasion strategies of pathogens—Acquisition of inhibitors and beyondMolecular Immunology, 2009
- Complement activation and inhibition: a delicate balanceTrends in Immunology, 2009
- MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- The glycoprotein-hormones activin A and inhibin A interfere with dendritic cell maturationReproductive Biology and Endocrinology, 2008
- A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β– and retinoic acid–dependent mechanismThe Journal of Experimental Medicine, 2007
- C4b Binding Protein Binds to CD154 Preventing CD40 Mediated Cholangiocyte Apoptosis: A Novel Link between Complement and Epithelial Cell SurvivalPLOS ONE, 2007
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996